Reviews/Alcohol and Health/Alcohol raises overall cancer risk
Cancer · ALC-CA-01 · v2
Several independent human studies in this corpus point the same way: drinking alcohol raises the risk of particular cancers. The strongest evidence is for colorectal cancer, where a genetic analysis supports cause and not just association [26], for esophageal cancer, where risk rises with intake and falls after quitting [27], and for a range of gut cancers that get more likely as alcohol intake climbs [25]. A laboratory study also shows alcohol speeding up liver tumour development in a hepatitis-B setting [21]. The catch is that no single study here measured 'overall' (all-cancer) risk directly, so the general claim is pieced together from these separate cancer sites, and much of the risk is concentrated in heavy drinkers and in people already at high risk. That is why the panel treated the directional claim as well supported but short of settled.
Primary human studies show alcohol raising risk across distinct cancer sites: each extra 14 g/day of alcohol was tied to a 10% higher colorectal cancer risk (OR 1.10, 95% CI 1.07-1.13), with Mendelian-randomisation support for causality (OR 1.25 per 1 SD, 95% CI 1.01-1.57) [26]; esophageal squamous cell cancer rose with each 22 g ethanol increment and fell with cessation (HR 0.52, 95% CI 0.31-0.88) [27]; and gastrointestinal cancer risk rose across steatotic-liver subgroups in step with alcohol intake [25]. A preclinical study shows alcohol enhancing HBV-induced liver carcinogenesis [21], and a 20-person crossover trial found hormonal shifts 'suggesting higher BC risk' [10]. No study in the corpus reports a composite all-cancer endpoint, so 'overall' risk is an aggregation across these separate sites. The contested point: The division is over scope and dose: the claim speaks of 'overall' cancer risk, yet the corpus holds only site-specific endpoints and the colorectal association 'was primarily driven by heavy alcohol consumption (>28 g/d)' with a J-shaped curve once non-drinkers are included [26], alongside adjusted hazard ratios as low as 0.75 in one subgroup [25]. Whether site-specific, heavy-drinking-weighted findings license a blanket statement about all-cancer risk at any intake is the open point.
All 27 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Alcohol and Health, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The claim concerns 'overall' (all-site) cancer risk, but no eligible primary study reports a composite all-cancer endpoint; the verdict is assembled from site-specific studies (colorectal [26], esophageal [27], GI [25], liver [21]). The aggregate-evidence papers (GBD, burden PAF, the Carr synthesis) were removed by the study-type filter.
The relationship is dose-dependent, not blanket: [26] states the CRC association 'was primarily driven by heavy alcohol consumption (>28 g/d)' with a J-shaped association including non-drinkers, and [25] reports aHRs as low as 0.75 in MASLD. A reading that any consumption increases cancer risk overstates the corpus.
Where it remains uncertain. The association is heavy-drinking-driven and J-shaped at low intake [26], with some subgroup hazard ratios below 1.0 [25], and no corpus study reports a composite all-cancer endpoint.
Aleatory
Risk is concentrated in heavy drinkers (>28 g/d) and J-shaped at low intake [26], and adjusted hazard ratios vary by subgroup, some below 1.0 [25].
Epistemic
The corpus contains no primary study reporting a composite all-cancer outcome; aggregate syntheses were removed by the study-type filter.
The load-bearing papers from a corpus of 27, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Mechanistic support that alcohol promotes hepatocarcinogenesis (single site, HBV context).
“Chronic alcohol consumption synergistically enhances hepatocellular carcinoma (HCC) risk in HBV-infected individuals.”
Panel auditInternal validity: low · scope of inference: Alcohol's promotion of HCC specifically in HBV-infected (HBx) contexts.Key limitations: animal/cell models · HBV-specific context · liver cancer only
Large nationwide cohort showing an alcohol-graded gradient in gastrointestinal cancer risk.
“For oesophageal, gastric and colorectal cancers, the aHRs ranged from 0.75 to 1.26 in MASLD, from 1.09 to 1.44 in MetALD and from 1.13 to 2.48 in ALD, indicating increasing risk with greater alcohol consumption.”
Panel auditInternal validity: medium · scope of inference: GI-cancer risk across MASLD/MetALD/ALD subtypes in a Japanese insured population.Key limitations: alcohol proxied by disease subtype · claims-database confounding · digestive cancers only
Direct observational dose-response for colorectal cancer; the heavy-driven qualifier bounds the claim.
“MR analyses supported that higher genetically predicted alcohol consumption was associated with CRC risk (ORIVW-per 1SD = 1.25; 95% CI: 1.01, 1.57)”
Panel auditInternal validity: high · scope of inference: Alcohol and colorectal cancer risk, overall and by molecular subtype.Key limitations: colorectal cancer only · J-shaped when nondrinkers included · association driven by heavy consumption (>28 g/d)
Surrogate-endpoint signal for breast cancer; weak (hormonal, N=20, not incidence).
“Five ounces of white wine daily did not lead to statistically significant increases in estradiol, but it led to changes in other sex hormones suggesting higher BC risk.”
Panel auditInternal validity: low · scope of inference: Short-term hormone changes after 5 oz daily wine in 20 postmenopausal ER+ breast-cancer survivors on aromatase inhibitors.Key limitations: tiny pilot sample · surrogate hormone endpoints · non-significant primary outcome · special population
4 of 27 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, partly causal site-specific evidence carries the directional claim, but scope indirectness and dose-dependence cap confidence below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No composite all-cancer endpoint. The claim is about overall risk, but every eligible study reports a single site, so 'overall' is inferred rather than measured. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective cohort or pooled individual-participant analysis with a pre-specified all-site incident-cancer endpoint across the alcohol-intake range.
Open question: Does alcohol raise composite all-cancer incidence, as opposed to the specific sites measured here? Why it is still open: No eligible primary study in the corpus reports an all-cancer endpoint; aggregate syntheses were excluded by the study-type filter.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19